Eli Lilly and Company is set to channel $1 billion into expanding its contract manufacturing operations in India. The U.S. drugmaker aims to position the country as a critical manufacturing base within its global supply network, with a primary goal of supplying medicines produced in India to international markets.
According to details released Tuesday, the investment will focus on strengthening production capabilities and broadening the company’s local footprint.
- Global Export Hub: India will serve as a key node for large-scale drug manufacturing for global distribution.
- New Therapy Launches: Eli Lilly intends to introduce more advanced therapies locally, including its Alzheimer’s drug, donanemab.
This sizable investment highlights India’s rising status in the global pharmaceutical value chain. As multinational companies seek to diversify and strengthen their supply chains, India is increasingly becoming a preferred destination for high volume, high-quality drug manufacturing and export operations.